ZNF160

Across TCGA pan-cancer cohorts, ZNF160 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of ZNF160’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ZNF160 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ZNF160 is over-expressed in tumor, although a few such as KICH and BRCA show the opposite, repressed pattern.

KIRC, COAD, and CHOL are the cancer types where ZNF160 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZNF160 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+0.562	<.001	8	view →
COAD	Male	IV	+0.736	.003	6	view →
CHOL	Female	All	+1.760	<.001	5	view →
KICH	All	All	−0.556	<.001	4	view →
BRCA	Female	All	−0.185	.012	4	view →
THCA	All	II,III,IV	−0.383	.005	3	view →
KIRP	All	IV	+0.822	.004	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

ZNF160–KIRC

Open the KIRC breakdown →